Lung deposition of formoterol in COPD patients: comparison of formoterol HFA pMDI, and formoterol dry powder inhaler

F. Mariotti, G. Poli, D. Acerbi, C. Herpich, P. Brand, J. Gleske, T. Meyer (Parma, Italy; Gauting, Germany)

Source: Annual Congress 2007 - New developments in thoracic imaging modalities and illustrated thorax pathologies
Session: New developments in thoracic imaging modalities and illustrated thorax pathologies
Session type: Thematic Poster Session
Number: 721
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
F. Mariotti, G. Poli, D. Acerbi, C. Herpich, P. Brand, J. Gleske, T. Meyer (Parma, Italy; Gauting, Germany). Lung deposition of formoterol in COPD patients: comparison of formoterol HFA pMDI, and formoterol dry powder inhaler. Eur Respir J 2007; 30: Suppl. 51, 721

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Non-inferiority comparison of formoterol HFA (FM-HFA) pMDI with formoterol CFC (FM-CFC) pMDI in patients with symptomatic asthma
Source: Eur Respir J 2007; 30: Suppl. 51, 358s
Year: 2007

Non-inferiority comparison of ipratropium-salbutamol HFA (IB/SAL-HFA) pMDI with ipratropium salbutamol CFC (IF/SAL-CFC) pMDI in patients with COPD
Source: Eur Respir J 2007; 30: Suppl. 51, 611s
Year: 2007

Comparison of two budesonide powder inhalers, Giona Easyhaler® and Pulmicort Turbuhaler® in steroid-naive asthmatic patients
Source: Eur Respir J 2001; 18: Suppl. 33, 100s
Year: 2001

Beclometasone/formoterol administered via extrafine dry powder inhaler in controlled asthmatic patients: Comparison with pMDI and beclometasone monotherapy
Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma
Year: 2012


Lung deposition of the extrafine dry powder fixed combination beclomethasone dipropionate plus formoterol fumarate via the NEXT DPI® in healthy subjects, asthmatic and COPD patients
Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I
Year: 2011

Non inferiority comparison of salmeterol HFA (SM-HFA) pMDI with salmeterol CFC (SM-CFC) pMDI in patients with symptomatic asthma
Source: Eur Respir J 2007; 30: Suppl. 51, 357s
Year: 2007

Non-inferiority comparison of budesonide HFA (BUD-HFA) pMDI with budesonide CFC (BUD-CFC) pMDI in patients with persistent moderate asthma
Source: Annual Congress 2008 - Wider aspects of managing respiratory disease in primary care
Year: 2008


Formoterol hydrofluoroalkane (HFA) pMDI has as rapid an onset of action as salbutamol HFA pMDI in asthma
Source: Eur Respir J 2003; 22: Suppl. 45, 285s
Year: 2003

Comparison of a formoterol multiple dose dry powder inhaler (MDPI) with a formoterol single dose dry powder inhaler (SDPI) in patients with moderate to severe asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 260s
Year: 2004

Comparability of formoterol dry powder (DPI) and metered dose inhalers (MDI) in asthma
Source: Eur Respir J 2005; 26: Suppl. 49, 50s
Year: 2005

Does Clickhaler match the Turbuhaler for efficacy of inhaled budesonide?
Source: Eur Respir J 2005; 26: Suppl. 49, 339s
Year: 2005

Cost-effectiveness of budesonide and formoterol in a single inhaler compared to fluticasone in the treatment of asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 157s
Year: 2001

Improved asthma control with budesonide/formoterol in a single inhaler, compared with budesonide alone
Source: Eur Respir J 2001; 18: 262-268
Year: 2001



Formoterol via turbuhaler (F) versus salbutamol via pressurized metered-dose inhaler (SB) in acute exacerbations of COPD
Source: Eur Respir J 2001; 18: Suppl. 33, 425s
Year: 2001

Comparison of a new HFA 134a-formulated budesonide pMDI with a standard CFC-formulated budesonide pMDI in children with persistent asthma
Source: Eur Respir J 2005; 26: Suppl. 49, 160s
Year: 2005

Salmeterol metered dose inhaler (MDI) propelled by hydrofluoroalkane (HFA) is non-inferior to salmeterol chlorofluorocarbon (CFC) propelled MDI in paediatic patients with persistent asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 583s
Year: 2004

Efficacy of formoterol 12μg dry powder capsules in 6,155 asthmatic patients poorly controlled with salmeterol or on-demand salbutamol (EFORA study)
Source: Eur Respir J 2002; 20: Suppl. 38, 107s
Year: 2002

Formoterol: a new pMDI CFC free formulation. Efficacy of the 12µg dosage versus a dry powder inhaler in moderate to severe asthmatic patients
Source: Eur Respir J 2003; 22: Suppl. 45, 284s
Year: 2003

Device preference and efficacy of formoterol aerolizer and salbutamol MDI in children with asthma
Source: Eur Respir J 2003; 22: Suppl. 45, 134s
Year: 2003

The novel budesonide HFA pMDI is clinically comparable to the conventional budesonide CFC pMDI in paediatric patients with asthma
Source: Eur Respir J 2005; 26: Suppl. 49, 160s
Year: 2005